Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies
- 5 December 2019
- journal article
- editorial
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 47 (3), 519-522
- https://doi.org/10.1007/s00259-019-04580-5
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With HyperthyroidismJAMA Internal Medicine, 2019
- I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an “inconvenient” truth?European Journal of Nuclear Medicine and Molecular Imaging, 2018
- Power of Absolute Values to Avoid Data Misinterpretations: The Case of Radioiodine-Induced Leukemia and MyelodysplasiaJournal of Clinical Oncology, 2018
- Risk of Hematologic Malignancies After Radioactive Iodine Treatment of Thyroid Cancer: An Unjustified WarningJournal of Clinical Oncology, 2018
- Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid CancerJournal of Clinical Oncology, 2018
- Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodineLeukemia, 2017
- DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine TherapyJournal of Nuclear Medicine, 2015
- 131I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignanciesNuklearmedizin-Nuclear Medicine, 2011
- Acute Myeloid Leukemia Following Prolonged Iodine-131 Therapy for Metastatic Thyroid CarcinomaScience, 1956
- RADIOACTIVE IODINE THERAPYJAMA, 1946